How to kill Pseudomonas-emerging therapies for a challenging pathogen

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antibiotic resistance (AR) is a growing global health crisis, particularly concerning for difficult-to-treat pathogens like Pseudomonas aeruginosa.
• Certain P. aeruginosa strains exhibit resistance to all currently available antibiotics, necessitating urgent development of new therapeutic strategies.

Purpose of the Study:

• To review the multifaceted resistance mechanisms employed by P. aeruginosa.
• To summarize diverse therapeutic approaches to overcome antibiotic resistance in P. aeruginosa infections.
• To provide an update on the clinical pipeline and future research directions for antipseudomonal therapies.

Main Methods:

• Comprehensive literature review of P. aeruginosa antibiotic resistance.
• Identification and categorization of intrinsic, acquired, and adaptive resistance mechanisms.
• Analysis of emerging therapeutic strategies including antimicrobial peptides, bacteriophage therapy, vaccines, monoclonal antibodies, drug combinations, and antivirulence therapies.

Main Results:

• P. aeruginosa utilizes intrinsic, acquired, and adaptive mechanisms to evade antibiotic action.
• Promising strategies to combat resistance include antimicrobial peptides, bacteriophage therapy, immune-based treatments, and drug combinations.
• The clinical pipeline for antipseudomonal therapies is advancing, with several novel approaches under investigation.

Conclusions:

• A multifaceted approach combining novel therapeutics and strategic drug development is crucial to combat P. aeruginosa antibiotic resistance.
• Antimicrobial peptides and bacteriophage therapy show potential for low resistance evolution.
• Further research into drug combinations, antivirulence strategies, and immune-based treatments is warranted to address the challenge of multidrug-resistant P. aeruginosa.